Oruka Therapeutics will present Week 16 data for ORKA-001 in psoriasis on October 26, 2026, via webcast.
Investivoq AI Summary
Oruka Therapeutics, Inc. has announced that it will present Week 16 data for its ORKA-001 treatment from the EVERLAST-B Phase 2b trial for moderate-to-severe plaque psoriasis on October 26, 2026. A conference call and webcast to discuss these results will take place at 8:00 a.m. ET on the same day, accessible through Oruka's website. The company focuses on developing innovative biologics aimed at improving treatment for chronic skin conditions like plaque psoriasis and hidradenitis suppurativa, with the goal of achieving high disease clearance rates and minimizing the frequency of dosing for patients.
Potential Positives
- Oruka Therapeutics is set to report significant data from the Phase 2b trial of ORKA-001, which could potentially impact the treatment landscape for chronic skin diseases such as plaque psoriasis.
- The announcement of a conference call and webcast for discussing the trial results indicates transparency and engagement with investors and stakeholders.
- Oruka’s focus on developing biologics with infrequent dosing may highlight its innovative approach and commitment to improving patient outcomes in chronic skin diseases.
Potential Negatives
- The press release does not provide any interim results or updates from the ongoing EVERLAST-B Phase 2b trial, which may raise concerns about the progress or potential efficacy of ORKA-001 in addressing chronic skin diseases.
- The announcement specifically mentions that the results will be reported in the future without any preliminary data, potentially indicating a lack of positive initial findings that could have strengthened investor confidence.
- The reliance on future data reporting may cause uncertainty among stakeholders regarding the company's current standing in clinical development and market competitiveness.
FAQ
What is the latest announcement from Oruka Therapeutics?
Oruka Therapeutics announced it will report Week 16 data for ORKA-001 from the EVERLAST-B Phase 2b trial on October 26, 2026.
When will Oruka host a conference call about the trial results?
The conference call will take place on Monday, October 26, 2026, at 8:00 a.m. ET.
How can I access the webcast for the EVERLAST-B trial results?
The live webcast can be accessed via a link provided on the Investors section of Oruka's website.
What chronic skin diseases is Oruka Therapeutics focused on?
Oruka Therapeutics is focused on treating chronic skin diseases such as plaque psoriasis and hidradenitis suppurativa.
Where can I find more information about Oruka Therapeutics?
More information can be found on Oruka's website at www.orukatx.com and their LinkedIn page.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
EARLY ACCESS
Receive ORKA Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$ORKA Insider Trading Activity
$ORKA insiders have traded $ORKA stock on the open market 98 times in the past 6 months. Of those trades, 0 have been purchases and 98 have been sales.
Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT sold 3,553,410 shares for an estimated $300,014,406
- LAWRENCE OTTO KLEIN (Chief Executive Officer) has made 0 purchases and 8 sales selling 104,181 shares for an estimated $9,333,252.
- CARL DAMBKOWSKI has made 0 purchases and 5 sales selling 140,000 shares for an estimated $8,645,748.
- PAUL T QUINLAN (General Counsel) has made 0 purchases and 17 sales selling 72,772 shares for an estimated $7,435,086.
- ARJUN AGARWAL (Senior Vice President, Finance) has made 0 purchases and 29 sales selling 62,281 shares for an estimated $5,118,995.
- JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 25 sales selling 43,894 shares for an estimated $3,628,154.
- LAURA LEE SANDLER (Chief Operating Officer) has made 0 purchases and 13 sales selling 16,506 shares for an estimated $1,379,091.
To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.
$ORKA Hedge Fund Activity
We have seen 180 institutional investors add shares of $ORKA stock to their portfolio, and 70 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 3,401,639 shares (+inf%) to their portfolio in Q2 2026, for an estimated $323,733,983
- FMR LLC added 1,626,242 shares (+21.9%) to their portfolio in Q2 2026, for an estimated $154,769,451
- RA CAPITAL MANAGEMENT, L.P. added 1,554,597 shares (+inf%) to their portfolio in Q2 2026, for an estimated $147,950,996
- BLACKROCK, INC. added 1,463,094 shares (+41.5%) to their portfolio in Q2 2026, for an estimated $139,242,655
- VIKING GLOBAL INVESTORS LP removed 1,163,212 shares (-43.6%) from their portfolio in Q2 2026, for an estimated $110,702,886
- BELLEVUE GROUP AG added 1,150,182 shares (+226.9%) to their portfolio in Q2 2026, for an estimated $109,462,820
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,103,743 shares (+inf%) to their portfolio in Q2 2026, for an estimated $105,043,221
To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.
$ORKA Price Targets
Multiple analysts have issued price targets for $ORKA recently. We have seen 3 analysts offer price targets for $ORKA in the last 6 months, with a median target of $130.0.
Here are some recent targets:
- Michael Yee from UBS set a target price of $130.0 on 07/01/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $120.0 on 06/23/2026
- Julian Harrison from BTIG set a target price of $151.0 on 05/14/2026
Full Release
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
Webcast Details
Oruka Therapeutics’ live webcast of the EVERLAST-B results will begin on Monday, October 26
th
, at 8:00 a.m. ET. The live webcast can be accessed via this
link
, or through the Investors section on the company’s website at
https://ir.orukatx.com/news-events/events-presentations
. A replay of the webcast will be available following the call.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit
www.orukatx.com
and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
